Global Companion Diagnostic Tests in Oncology Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
SKU ID :GIR-12796536 | Published Date: 13-Sep-2018 | No. of pages: 118Description
Increasing incidence of cancer, rising cost burden of cancer treatment, and increasing mortalities due to cancer, are some of the major reasons for increasing demand for new and technologically advanced treatment options, therapies, and drugs for the treatment of cancer.
Scope of the Report:
This report studies the Companion Diagnostic Tests in Oncology market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Companion Diagnostic Tests in Oncology market by product type and applications/end industries.
The global Companion Diagnostic Tests in Oncology market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Companion Diagnostic Tests in Oncology.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Abbott
Roche
Genomic Health
QIAGEN
Agilent
Agendia
BioMerieux
Illumina
Siemens Healthcare
Thermo Fisher
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Protein Detection
DNA Detection
Market Segment by Applications, can be divided into
Pharmaceutical & Biotechnology Companies
Medical Device Companies
Research Institutes
Scope of the Report:
This report studies the Companion Diagnostic Tests in Oncology market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Companion Diagnostic Tests in Oncology market by product type and applications/end industries.
The global Companion Diagnostic Tests in Oncology market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Companion Diagnostic Tests in Oncology.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Abbott
Roche
Genomic Health
QIAGEN
Agilent
Agendia
BioMerieux
Illumina
Siemens Healthcare
Thermo Fisher
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Protein Detection
DNA Detection
Market Segment by Applications, can be divided into
Pharmaceutical & Biotechnology Companies
Medical Device Companies
Research Institutes
TOC
Tables & Figures
Companies
- PRICE
-
$3480$6960Buy Now